Looking to identify a new antibody therapeutic target?
Would it be helpful to know what your peers viewed as being their top challenge so that you can design your pipelines with this in mind?
Our 2012 European Antibody Congress Survey revealed that there are a multitude of challenges when identifying a new target, but the one which was mentioned more than any other was the limitation of preclinical models for evaluating and capturing the full complexity of the diseases mechanism of action.
Do you have a strategy for overcoming this challenge?
Do you want to find out what else our survey showed?